Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
Inhibiting TGF-β1 to increase immune responses against tumors bears the risk of tumor-promoting toxicity. Here the authors show that selectively blocking TGF-β1 produced by immunosuppressive cells is feasible with anti-GARP:TGF-β1 antibodies and improves the efficacy of PD-1 blockade immunotherapy....
Enregistré dans:
Auteurs principaux: | Grégoire de Streel, Charlotte Bertrand, Nicolas Chalon, Stéphanie Liénart, Orian Bricard, Sara Lecomte, Julien Devreux, Mélanie Gaignage, Gitte De Boeck, Lore Mariën, Inge Van De Walle, Bas van der Woning, Michael Saunders, Hans de Haard, Elien Vermeersch, Wim Maes, Hans Deckmyn, Pierre G. Coulie, Nicolas van Baren, Sophie Lucas |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/8a55d3ad04c940c5ae3df3fd9a81d1dc |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
par: Hyun Tae Lee, et autres
Publié: (2017) -
Targeting PD-1/PD-L1 in lung cancer: current perspectives
par: González-Cao M, et autres
Publié: (2015) -
Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
par: LAI Yanliang, et autres
Publié: (2021) -
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
par: Zhitao Li, et autres
Publié: (2021) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
par: Utpal Kumar, et autres
Publié: (2021)